Once-daily abacavir in place of twice-daily administration

Amber M Goedken; Ronald A Herman

doi:10.1345/aph.1E680

Back

Once-daily abacavir in place of twice-daily administration

Journal article

Peer reviewed

Once-daily abacavir in place of twice-daily administration

Amber M Goedken and Ronald A Herman

The Annals of pharmacotherapy, Vol.39(7-8), pp.1302-1308

07/2005

DOI: 10.1345/aph.1E680

PMID: 15956231

View Online

Abstract

To review the safety and efficacy of a once-daily dosage regimen for abacavir, a nucleoside reverse transcriptase inhibitor. English-language MEDLINE and Iowa Drug Information Service database reports were accessed from 1966 to March 2005. International Pharmaceutical Abstracts was searched from 1970 to March 2005. The key words used in all searches were abacavir and Ziagen. Article bibliographies were used to identify additional relevant articles. The Internet was searched to identify abstracts of poster and oral presentations that have not yet been published. The manufacturer was also contacted to obtain unpublished information. Publications were included that provided information related to the safety and efficacy of abacavir when used once daily. Preference was given to randomized, double-blind, controlled trials comparing once-daily abacavir regimens with other antiretroviral regimens. Abstracts from professional meetings were included for unpublished studies, and conference coverage reviews were included if the abstracts were not available. In trials directly comparing once- and twice-daily abacavir, little difference was shown in the efficacy of the 2 regimens. Despite similar adverse effect profiles, significantly more severe hypersensitivity reactions and severe diarrhea were seen with once-daily abacavir in one trial. Once-daily administration of abacavir has not been shown to be inferior to twice-daily dosing, but it may put patients at increased risk for severe hypersensitivity reactions and diarrhea. More data are needed to confirm this risk.

Dideoxynucleosides - administration & dosage

Anti-HIV Agents - adverse effects

Humans

Clinical Trials as Topic

Reverse Transcriptase Inhibitors - administration & dosage

Anti-HIV Agents - administration & dosage

Dideoxynucleosides - pharmacokinetics

Reverse Transcriptase Inhibitors - adverse effects

Reverse Transcriptase Inhibitors - pharmacokinetics

Anti-HIV Agents - pharmacokinetics

Anti-HIV Agents - therapeutic use

HIV Infections - drug therapy

Dideoxynucleosides - adverse effects

Dideoxynucleosides - therapeutic use

Reverse Transcriptase Inhibitors - therapeutic use

Details

Title: Subtitle: Once-daily abacavir in place of twice-daily administration
Creators: Amber M Goedken - Iowa Drug Information Network, Iowa City, IA 52242-5000, USA
Ronald A Herman
Resource Type: Journal article
Publication Details: The Annals of pharmacotherapy, Vol.39(7-8), pp.1302-1308
Publisher: United States
DOI: 10.1345/aph.1E680
PMID: 15956231
ISSN: 1060-0280
eISSN: 1542-6270
Language: English
Date published: 07/2005
Academic Unit: Pharmacy Practice and Science
Record Identifier: 9984065500602771

Metrics

19 Record Views

5 Times Cited - Web of Science